<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203311435266</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203311435266</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Association of chemokine CXCL12-3′G801A polymorphism with systemic lupus erythematosus in a Han Chinese population</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Wu</surname><given-names>F-X</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311435266">1</xref>
<xref ref-type="aff" rid="aff2-0961203311435266">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Luo</surname><given-names>X-Y</given-names></name>
<xref ref-type="aff" rid="aff2-0961203311435266">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wu</surname><given-names>L-J</given-names></name>
<xref ref-type="aff" rid="aff3-0961203311435266">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yang</surname><given-names>M-H</given-names></name>
<xref ref-type="aff" rid="aff2-0961203311435266">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Long</surname><given-names>L</given-names></name>
<xref ref-type="aff" rid="aff4-0961203311435266">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Liu</surname><given-names>N-T</given-names></name>
<xref ref-type="aff" rid="aff5-0961203311435266">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhou</surname><given-names>B</given-names></name>
<xref ref-type="aff" rid="aff4-0961203311435266">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zeng</surname><given-names>X-f</given-names></name>
<xref ref-type="aff" rid="aff6-0961203311435266">6</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Yang</surname><given-names>C-de</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311435266">1</xref>
<xref ref-type="corresp" rid="corresp2-0961203311435266"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Yuan</surname><given-names>G-H</given-names></name>
<xref ref-type="aff" rid="aff2-0961203311435266">2</xref>
<xref ref-type="corresp" rid="corresp1-0961203311435266"/>
</contrib>
</contrib-group>
<aff id="aff1-0961203311435266"><label>1</label>Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China</aff>
<aff id="aff2-0961203311435266"><label>2</label>Institute of Rheumatology and Immunology, North Sichuan Medical College, Nanchong, PR China</aff>
<aff id="aff3-0961203311435266"><label>3</label>Department of Rheumatology, People's Hospital of XinJiang Uygur Autonomus Region, Urumchi, PR China</aff>
<aff id="aff4-0961203311435266"><label>4</label>Department of Rheumatology, People's Hospital of Sichuan Province, Chendu City, PR China</aff>
<aff id="aff5-0961203311435266"><label>5</label>Department of Rheumatology, Suining Municipal People’s Hospital, Suining City, PR China</aff>
<aff id="aff6-0961203311435266"><label>6</label>Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, PR China</aff>
<author-notes>
<corresp id="corresp1-0961203311435266">Guo‐Hua Yuan, Institute of Rheumatology and Immunology, Affiliated Hospital, North Sichuan Medical College, 87 Wenhua Road, Nanchong 637000, Sichuan, PR China Email: <email>ghuayuan1996@yahoo.com</email></corresp>
<corresp id="corresp2-0961203311435266">Cheng‐de Yang, Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, 145 Shan Dong Zhong Road, Shanghai 200001, China Email: <email>yangchengde@sina.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>21</volume>
<issue>6</issue>
<fpage>604</fpage>
<lpage>610</lpage>
<history>
<date date-type="received"><day>31</day><month>1</month><year>2011</year></date>
<date date-type="accepted"><day>13</day><month>12</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2012. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>CXCL12, also known as stromal cell-derived factor (SDF-1), is a CXC chemokine. Recent reports have shown that CXCL12 might play key roles in a murine model of lupus and in patients with systemic lupus erythematosus (SLE). A common variant at position 801 in 3′-untranslated region in CXCL12 gene (designated CXCL12-3′G801A) has been reported in association with autoimmune diseases, such as type 1 diabetes and systemic sclerosis. We investigated the influence of CXCL12-3′G801A polymorphism on susceptibility to SLE by genotyping this single nucleotide polymorphism in 422 SLE patients and 374 healthy controls. The frequency of G/G homozygote was observed in 60.0% of SLE patients and in 52.7% of healthy individuals (χ<sup>2 </sup>= 4.275, <italic>p</italic> = 0.039). Compared with patients with G/A and A/A genotype, SLE patients with G/G genotype were also more prone to developing photosensitivity (χ<sup>2 </sup>= 6.778, <italic>p</italic> = 0.034), renal damage (χ<sup>2 </sup>= 6.388, <italic>p</italic> = 0.041) and to producing antibodies against nucleosomes (χ<sup>2 </sup>= 8.341, <italic>p</italic> = 0.015). Moreover, the plasma level of CXCL12α was also significantly increased in patients with G/G homozygote than in healthy controls carrying the same genotype [(4067.0 ± 1092.3) pg/ml <italic>vs.</italic> (3278.5 ± 547.4) pg/ml, <italic>p</italic> = 0.002]. Our results suggest that polymorphism in CXCL12-3′G801A might be a genetic risk factor for developing SLE. The association of G/G homozygote with nephritis and skin damage developed in SLE patients might be due to its effects upon the production of auto-antibodies and CXCL12 protein.</p>
</abstract>
<kwd-group>
<kwd>Lupus erythematosus</kwd>
<kwd>systemic</kwd>
<kwd>polymorphism</kwd>
<kwd>single nucleotide</kwd>
<kwd>chemokine CXCL12</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203311435266" sec-type="intro"><title>Introduction</title>
<p>Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune dysregulation, including activation of auto-reactive T and B lymphocytes and complement system, immune complex generation and deposition. In patients suffering from SLE, there is pathological involvement of multiple organs, and the clinical manifestations are highly heterogeneous, ranging from mild skin rash and arthralgia/arthritis to severe damage of kidney and central nervous system. The etiology of SLE is largely unknown; genetic and environmental factors are thought to be involved in the onset of the disease.<sup><xref ref-type="bibr" rid="bibr1-0961203311435266">1</xref>,<xref ref-type="bibr" rid="bibr2-0961203311435266">2</xref></sup> A large number of genetic studies have been carried out and addressed the various candidate gene loci such as alleles of HLA-DR and HLA-DQ in HLA class II gene that may predispose to the pathogenesis of SLE.<sup><xref ref-type="bibr" rid="bibr3-0961203311435266">3</xref></sup></p>
<p>Infiltration and accumulation of inflammatory leukocytes mediate tissue injury and organ dysfunction in SLE.<sup><xref ref-type="bibr" rid="bibr4-0961203311435266">4</xref></sup> Leukocyte migration, under normal and inflammatory conditions, is regulated by the activity of various adhesion molecules and by the interaction of a number of chemokines and their specific receptors. CXCL12, also known as stromal cell-derived factor (SDF-1), is a chemokine that plays an important role in the regulation of migration, proliferation and differentiation of hematopoietic cells.<sup><xref ref-type="bibr" rid="bibr5-0961203311435266">5</xref></sup> High expression of CXCL12 has been documented in patients with SLE.<sup><xref ref-type="bibr" rid="bibr6-0961203311435266">6</xref></sup> Moreover, in the study conducted by Balabanian et al.,<sup><xref ref-type="bibr" rid="bibr7-0961203311435266">7</xref></sup> administration of antagonists of CXCL12/SDF-1 early in life prevented the development of autoantibodies, nephritis and death in NZB/W mice. Meanwhile, initiation of anti-CXCL12/SDF-1 mAb treatment later in life, in mice with established nephritis, inhibited autoantibody production, abolished proteinuria and immunoglobulin (Ig) deposition and reversed morphological changes in the kidneys. These results suggest that CXCL12 is a key molecule in the development of autoimmunity in the murine model of lupus.</p>
<p>The CXCL12 gene is located at band q11 on chromosome 10 and encodes for six isoforms of human CXCL12/SDF-1, known as SDF-1α and SDF-1β, SDF-1γ, SDF-1δ, SDF-1ɛ and SDF-1ζ, which are the result of alternative splicing events.<sup><xref ref-type="bibr" rid="bibr8-0961203311435266">8</xref></sup> A single-nucleotide polymorphism (SNP), designated CXCL12-3′G801A (rs1801157), was identified in the 3′ untranslated region (3′UTR) of the CXCL12β gene transcript and involves a G-to-A transition at nucleotide position +801 relative to the start codon. As the functions of SDF-1 are thought to be important for the pathogenesis of certain diseases, several studies have been carried out to examine an association between disease susceptibility and CXCL12-3′G801A polymorphism. Studies have suggested that the CXCL12-3′G801A polymorphism is associated with HIV infection,<sup><xref ref-type="bibr" rid="bibr9-0961203311435266">9</xref></sup> leukemia,<sup><xref ref-type="bibr" rid="bibr10-0961203311435266">10</xref>,<xref ref-type="bibr" rid="bibr11-0961203311435266">11</xref></sup> colorectal cancer,<sup><xref ref-type="bibr" rid="bibr12-0961203311435266">12</xref></sup> type I diabetes and systemic sclerosis.<sup><xref ref-type="bibr" rid="bibr13-0961203311435266">13</xref></sup> However, only a few studies concerning on the CXCL12-3′G801A polymorphism in patients suffering SLE have been performed. To clarify whether the CXCL12-3′G801A polymorphism is associated with disease susceptibility and clinical characteristics in SLE, we therefore investigated the distribution of CXCL12-3′G801A alleles and genotypes in SLE patients in a Han Chinese population, comparing them with a group of unrelated healthy controls.</p></sec>
<sec id="sec2-0961203311435266" sec-type="materials|methods"><title>Materials and methods</title>
<sec id="sec3-0961203311435266" sec-type="subjects"><title>Patients and controls</title>
<p>A total of 422 patients with systemic lupus erythematosus from a Han Chinese population was consecutively recruited from four different Chinese rheumatology centers. The mean age of patients with lupus was 36.3 years (range: 12–80 years), and median duration was 25.6 months. Thirty-one of them were male patients, and 391 were female. All of the patients included in our study satisfied the American College of Rheumatology (ACR) revised criteria for SLE.<sup><xref ref-type="bibr" rid="bibr14-0961203311435266">14</xref></sup> Individual clinical information and seroimmunological data, including antinuclear antibodies (ANAs) and antibodies against dsDNA, Sm and nuclear RNP (nRNP), were collected in detail. Three hundred and seventy-four unrelated healthy blood donors matched for sex and age from the same Chinese population served as controls. Written informed consent was obtained from all subjects and the study had approval from the ethical review committee of the four hospitals that participated.</p></sec>
<sec id="sec4-0961203311435266"><title>CXCL12-3′G801A polymorphism genotype evaluation</title>
<p>Peripheral EDTA-treated blood was collected from every participant, and genomic DNA was extracted by a commercial DNA extraction kit (TIANampDNA Blood Kit, China, commercial number: DP318–03). Genotyping for CXCL12-3′G801A was performed by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method as previously described by Winkler et al.<sup><xref ref-type="bibr" rid="bibr9-0961203311435266">9</xref></sup> Briefly, the primers used for genotyping were as follows: forward primer, 5′-CAG TCA ACC TGG GCA AAG CC-3′; reverse primer, 5′-AGC TTT GGT CCT GAG AGT CC-3′. Sample DNA (100 ng) was amplified by PCR under the following conditions: initiation at 94°C for 2 min followed by 35 cycles at 94°C for 30 s, annealing at 58°C for 30 s and extension at 72°C for 45 s and a final extension at 72°C for 10 min. PCR reaction yielded a 302 bp product. Since CXCL12 mutant allele A eliminated an Msp I restriction site, the PCR products were digested by the corresponding restriction enzyme Msp I (Fermentas, USA) at 37°C for 10 h. The digested products were visualized by electrophoresis on a 2% agarose gel (Oxoid Limited, Hampshire, UK) containing ethidium bromide (0.5 mg/ml). Samples exhibiting 302–bp band were assigned as A/A genotype, samples revealing two bands of 202 and 100 bp were typed as G/G genotype and samples illustrating three bands of 302, 202 and 100 bp were assigned as G/A genotype.</p></sec>
<sec id="sec5-0961203311435266"><title>Measurement of plasma CXCL12α by enzyme-linked immunosorbent assay</title>
<p>Plasma levels of CXCL12α were determined by a commercial specific enzyme-linked immunosorbent assay (ELISA) kit (R&amp;D Systems, Inc., USA) with sensitivity of 0.78 U/ml, according to the manufacturer's instruction. Briefly, standard and analyzed samples were added in duplicate to a 96-well microplate precoated with a monoclonal antibody specific for CXCL12α. After incubation and washing, an enzyme-linked mouse monoclonal antibody specific for human β2-microglobulin was pipetted into the wells. Following washing, a substrate solution was added to develop color reaction. Plates were read at 450nm in an ELISA reader and subtracted at 570 nm. All tests were performed at room temperature. A curve was prepared by plotting the optical density versus the concentration of CXCL12α in the standard wells. The concentration of CXCL12α in the unknown sample was determined by referring the observed optical density to the standard curve.</p></sec>
<sec id="sec6-0961203311435266"><title>Statistical analysis</title>
<p>Allele and genotype distributions of the studied population were obtained by direct counting. Hardy-Weinberg equilibrium and the difference of CXCL12-3′G801A genotype and allele frequencies between SLE patients and healthy subjects were examined by Pearson chi-square test or Fisher's exact test. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated as an estimation of relative risk for SLE. The plasma levels of CXCL12α in the three CXCL12-3′G801A genotypes were analyzed by Students’ <italic>t</italic>-test or ANOVA. Statistical analysis was done by SPSS software, version 11.5. Results were considered significant at <italic>p</italic>-value &lt; 0.05.</p></sec></sec>
<sec id="sec7-0961203311435266" sec-type="results"><title>Results</title>
<sec id="sec8-0961203311435266"><title>CXCL12-3′G801A polymorphism in SLE and controls</title>
<p>CXCL12-3′G801A allelic frequencies were in Hardy-Weinberg equilibrium (χ<sup>2 </sup>= 2.525, <italic>p</italic> = 0.283 for the control group and χ<sup>2 </sup>= 0.038, <italic>p</italic> = 0.981 for the SLE patients group). The frequencies of CXCL12-3′G801A alleles and genotypes in SLE patients and healthy subjects are reported in <xref ref-type="table" rid="table1-0961203311435266">Table 1</xref>. No significant difference was observed for the frequency of A and G alleles between the control group and the SLE group (χ<sup>2 </sup>= 2.193, <italic>p</italic> = 0.139), the OR for the A and G alleles was OR = 1.140, 95% CI = 0.958–1.356 and OR = 0.959, 95% CI = 0.907–1.014, respectively. The frequency of A/A genotype was relatively low in both SLE patients and controls (5.5 % <italic>vs.</italic> 4.5 %, <italic>p</italic> = 0.56), while the frequency of G/G homozygote genotype was more common in the SLE group than that in controls (SLE = 60.0% <italic>vs.</italic> controls = 52.7%, <italic>p</italic> = 0.039), and the frequency of G/A heterozygote was significantly decreased in SLE patients (SLE = 34.6% <italic>vs.</italic> controls = 42.8%, <italic>p</italic> = 0.018).
<table-wrap id="table1-0961203311435266" position="float"><label>Table 1</label><caption><p>Distribution of CXCL12-3′G801A genotypes and alleles in healthy control group and SLE group</p></caption>
<graphic alternate-form-of="table1-0961203311435266" xlink:href="10.1177_0961203311435266-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>HC n <italic>(</italic>%<italic>)</italic></th>
<th>SLE n <italic>(</italic>%<italic>)</italic></th>
<th>χ<sup>2</sup></th>
<th>p value</th>
<th>OR</th>
<th>CI</th></tr></thead>
<tbody align="left">
<tr>
<td> Allele</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td> A</td>
<td>194 (25.9)</td>
<td>192 (22.7)</td>
<td>2.193</td>
<td>0.139<sup><xref ref-type="table-fn" rid="table-fn1-0961203311435266">a</xref></sup></td>
<td>1.140</td>
<td>0.958 − 1.356</td></tr>
<tr>
<td> G</td>
<td>554 (74.1)</td>
<td>652 (77.3)</td>
<td/>
<td/>
<td>0.959</td>
<td>0.907 − 1.014</td></tr>
<tr>
<td> Total</td>
<td>748</td>
<td>844</td>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td>Genotype</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td> A/A</td>
<td>17 (4.5)</td>
<td>23 (5.5)</td>
<td>0.340</td>
<td>0.56<sup><xref ref-type="table-fn" rid="table-fn2-0961203311435266">b</xref></sup></td>
<td>1.199</td>
<td>0.651 − 2.210</td></tr>
<tr>
<td> G/A</td>
<td>160 (42.8)</td>
<td>146 (34.6)</td>
<td>5.611</td>
<td>0.018<sup><xref ref-type="table-fn" rid="table-fn3-0961203311435266">c</xref></sup></td>
<td>0.809</td>
<td>0.678 − 0.964</td></tr>
<tr>
<td> G/G</td>
<td>197 (52.7)</td>
<td>253 (60.0)</td>
<td>4.275</td>
<td>0.039<sup><xref ref-type="table-fn" rid="table-fn4-0961203311435266">d</xref></sup></td>
<td>1.138</td>
<td>1.006 − 1.288</td></tr>
<tr>
<td> Total</td>
<td>374</td>
<td>422</td>
<td/>
<td/>
<td/>
<td/></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203311435266"><label>a</label><p>A allele <italic>vs</italic>. G allele.</p></fn>
<fn id="table-fn2-0961203311435266"><label>b</label><p>A/A genotype <italic>vs</italic>. G/A and G/G genotype.</p></fn>
<fn id="table-fn3-0961203311435266"><label>c</label><p>G/A genotype <italic>vs</italic>. A/A and G/G genotype.</p></fn>
<fn id="table-fn4-0961203311435266"><label>d</label><p>G/G genotype <italic>vs.</italic> A/A and G/A genotype.</p></fn></table-wrap-foot>
</table-wrap></p></sec>
<sec id="sec9-0961203311435266"><title>CXCL12-3′G801A polymorphism genotypes and clinical profiles of SLE</title>
<p>To see whether the CXCL12-3′G801A polymorphism might also be associated with some special clinical features of SLE, we further analyzed the differences in clinical manifestations and laboratory profiles among patients with different CXCL12-3′G801A genotypes (<xref ref-type="table" rid="table2-0961203311435266">Table 2</xref>). We found that, as compared with SLE patients with G/A heterozygote, the patients with G/G homozygote had higher incidence of photosensitivity (χ<sup><xref ref-type="bibr" rid="bibr2-0961203311435266">2</xref></sup><sup> </sup>= 6.050, <italic>p</italic> = 0.014) and nephritis (χ<sup><xref ref-type="bibr" rid="bibr2-0961203311435266">2</xref></sup><sup> </sup>= 6.185, <italic>p</italic> = 0.013) and a higher positive rate of anti-nucleosomes antibody (χ<sup><xref ref-type="bibr" rid="bibr2-0961203311435266">2</xref></sup><sup> </sup>= 3.872, <italic>p</italic> = 0.049).
<table-wrap id="table2-0961203311435266" position="float"><label>Table 2</label><caption><p>Association of CXCL12-3′G801A genotypes with clinical features of systemic lupus erythematosus patients</p></caption>
<graphic alternate-form-of="table2-0961203311435266" xlink:href="10.1177_0961203311435266-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>A/A (n = 23) n <italic>(</italic>%<italic>)</italic></th>
<th>G/A (n = 146) n <italic>(</italic>%<italic>)</italic></th>
<th>G/G (n = 253) n <italic>(</italic>%<italic>)</italic></th>
<th>Χ<sup>2</sup></th>
<th>p value<sup><xref ref-type="table-fn" rid="table-fn5-0961203311435266">a</xref></sup></th></tr></thead>
<tbody align="left">
<tr>
<td>Skin rash</td>
<td>14 (60.9)</td>
<td>74 (50.7)</td>
<td>142 (56.1)</td>
<td>1.503</td>
<td>0.472</td></tr>
<tr>
<td>Photosensitivity</td>
<td>8 (34.8)</td>
<td>28 (19.2)</td>
<td>77 (30.4)<sup><xref ref-type="table-fn" rid="table-fn6-0961203311435266">b</xref></sup></td>
<td>6.778</td>
<td>0.034</td></tr>
<tr>
<td>Arthralgia/arthritis</td>
<td>17 (73.9)</td>
<td>91 (62.3)</td>
<td>164 (64.8)</td>
<td>1.201</td>
<td>0.549</td></tr>
<tr>
<td>Serositis</td>
<td>7 (30.4)</td>
<td>39 (26.7)</td>
<td>71 (28.1)</td>
<td>0.173</td>
<td>0.917</td></tr>
<tr>
<td>Nephritis</td>
<td>13 (56.2)</td>
<td>78 (53.4)</td>
<td>167 (66.0)<sup><xref ref-type="table-fn" rid="table-fn7-0961203311435266">c</xref></sup></td>
<td>6.388</td>
<td>0.041</td></tr>
<tr>
<td>CNS disorders</td>
<td>3 (13.0)</td>
<td>7 (4.8)</td>
<td>29 (11.5)</td>
<td>5.326</td>
<td>0.070</td></tr>
<tr>
<td>Leukocytopenia</td>
<td>9 (39.1)</td>
<td>67 (45.9)</td>
<td>133 (52.6)</td>
<td>2.704</td>
<td>0.259</td></tr>
<tr>
<td>Anemia</td>
<td>12 (52.2)</td>
<td>77 (52.7)</td>
<td>129 (51.0)</td>
<td>0.116</td>
<td>0.943</td></tr>
<tr>
<td>Thrombopenia</td>
<td>5 (21.7)</td>
<td>44 (30.1)</td>
<td>91 (36.0)</td>
<td>2.855</td>
<td>0.240</td></tr>
<tr>
<td>Anti‐dsDNA</td>
<td>6 (26.1)</td>
<td>47 (32.2)</td>
<td>106 (42.9)</td>
<td>5.105</td>
<td>0.078</td></tr>
<tr>
<td>Anti‐histone</td>
<td>4 (17.4)</td>
<td>46 (31.5)</td>
<td>77 (30.4)</td>
<td>1.917</td>
<td>0.384</td></tr>
<tr>
<td>Anti‐nucleosomes</td>
<td>5 (21.7)</td>
<td>55 (37.7)</td>
<td>121 (47.8)<sup><xref ref-type="table-fn" rid="table-fn8-0961203311435266">d</xref>,<xref ref-type="table-fn" rid="table-fn9-0961203311435266">e</xref></sup></td>
<td>8.341</td>
<td>0.015</td></tr>
<tr>
<td>Anti-U<sub>1</sub>-snRNP</td>
<td>9 (39.1)</td>
<td>63 (43.2)</td>
<td>89 (35.2)</td>
<td>2.504</td>
<td>0.286</td></tr>
<tr>
<td>Anti‐SSA</td>
<td>13 (56.5)</td>
<td>96 (65.8)</td>
<td>158 (64.5)</td>
<td>0.911</td>
<td>0.634</td></tr>
<tr>
<td>Anti‐SSB</td>
<td>5 (21.7)</td>
<td>56 (38.4)</td>
<td>82 (32.4)</td>
<td>3.063</td>
<td>0.216</td></tr>
<tr>
<td>Anti‐Sm</td>
<td>4 (17.4)</td>
<td>56 (38.4)</td>
<td>73 (28.9)</td>
<td>6.122</td>
<td>0.047</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0961203311435266"><label>a</label><p>2 × 3 chi‐square test.</p></fn>
<fn id="table-fn6-0961203311435266"><label>b</label><p>G/G homozygote <italic>vs</italic>. G/A heterozygote, χ<sup>2 </sup>= 6.050, <italic>p</italic> = 0.014.</p></fn>
<fn id="table-fn7-0961203311435266"><label>c</label><p>G/G homozygote <italic>vs</italic>. G/A heterozygote, χ<sup>2 </sup>= 6.185, <italic>p</italic> = 0.013.</p></fn>
<fn id="table-fn8-0961203311435266"><label>d</label><p>G/G homozygote <italic>vs</italic>. G/A heterozygote, χ<sup>2 </sup>= 3.872, <italic>p</italic> = 0.049.</p></fn>
<fn id="table-fn9-0961203311435266"><label>e</label><p>G/G homozygote <italic>vs</italic>. A/A homozygote, χ<sup>2 </sup>= 5.783, <italic>p</italic> = 0.016.</p></fn>
<fn id="table-fn10-0961203311435266"><p>CNS: central nervous system.</p></fn></table-wrap-foot>
</table-wrap></p></sec>
<sec id="sec10-0961203311435266"><title>Plasma level of CXCL12α in SLE patients and controls</title>
<p>The plasma level of CXCL12α in 54 SLE patients was significantly higher than that in 27 healthy controls [(3894.6 ± 1070.6) pg/ml <italic>vs.</italic> (3366.9 ± 562.7) pg/ml, <italic>p</italic> = 0.005]. The levels of CXCL12α in plasma samples from SLE patients and healthy controls with different CXCL12-3′G801A genotypes are reported in <xref ref-type="fig" rid="fig1-0961203311435266">Figure 1</xref>. In SLE patients, individuals with G/G homozygote had the highest plasma levels of CXCL12α [(4067.0 ± 1092.3) pg/ml], and individuals with A/A homozygote had the lowest levels of CXCL12α [(3318.4 ± 228.3) pg/ml], although it was not statistically significant. Moreover, the plasma levels of CXCL12α were significantly elevated in SLE patients with G/G homozygote compared with those in healthy controls carrying the same genotype [(4067.0 ± 1092.3) pg/ml <italic>vs.</italic> (3278.5 ± 547.4) pg/ml, <italic>p</italic> = 0.002]. No difference in the plasma levels of CXCL12α was found among SLE patients and healthy controls with G/A or A/A genotype.
<fig id="fig1-0961203311435266" position="float"><label>Figure 1</label><caption><p>The production of CXCL12α in SLE patients and healthy controls (HC group) carrying different CXCL12-3′G801A genotypes.</p></caption><graphic xlink:href="10.1177_0961203311435266-fig1.tif"/></fig></p></sec></sec>
<sec id="sec11-0961203311435266" sec-type="discussion"><title>Discussion</title>
<p>SLE is characterized by the production of auto-antibodies and the damage in multiple organs. Infiltration and accumulation of inflammatory leukocytes is a critical process in the pathogenesis of tissue injury in SLE.<sup><xref ref-type="bibr" rid="bibr4-0961203311435266">4</xref></sup> The recruitment of inflammatory cells to lesions is an essential step in the development and progression of inflammation, and chemokines are important actors in this immune mediated process. CXCL12 is a CXC chemokine which has been proved to play a significant role in the development of autoimmunity in a murine model of lupus.<sup><xref ref-type="bibr" rid="bibr7-0961203311435266">7</xref></sup> A common polymorphism variant, defined by a G→A mutation and located at position 801 in 3′UTR in CXCL12 gene (designated CXCL12-3′G801A), has been documented elsewhere.<sup>9–11</sup> This polymorphism has been considered a factor in increased susceptibility to many different types of carcinomas (lymphoma, oral squamous carcinomas and cancers of the breast, lung and prostate), and chronic myeloproliferative disease.<sup>10–12</sup> Moreover, the association of CXCL12-3′G801A allele with autoimmune diseases such as systemic sclerosis and type 1 diabetes mellitus has also been reported.<sup><xref ref-type="bibr" rid="bibr15-0961203311435266">15</xref>,<xref ref-type="bibr" rid="bibr16-0961203311435266">16</xref></sup></p>
<p>Ye et al.<sup><xref ref-type="bibr" rid="bibr17-0961203311435266">17</xref></sup> and Warchoł et al.<sup><xref ref-type="bibr" rid="bibr18-0961203311435266">18</xref></sup> had genotyped the CXCL12-3′G801A polymorphism in 143 SLE patients from an eastern area of China and 150 SLE patients from Poland respectively; no association of CXCL12-3′G801A polymorphism with SLE had been found. Lima et al.<sup><xref ref-type="bibr" rid="bibr19-0961203311435266">19</xref></sup> also had the CXCL12-3′G801A polymorphism genotyped in a relatively large number of Mexican SLE patients (242 patients). A trend of the increased frequency of G/G homozygote was noticed in SLE patients (71.5% <italic>vs.</italic> 64.5%). In this study, we also have investigated the role of the CXCL12-3′G801A polymorphism in susceptibility to SLE, in 422 patients from western and northern areas of China. We demonstrated that there was a significant association of the G/G homozygote in CXCL12-3′G801A gene with SLE (60.0% <italic>vs.</italic> 52.7%, OR = 1.149, 95% CI = 1.020 − 1.295, <italic>p</italic> = 0.039). Our results indicate that the CXCL12-3′G801A G/G genotype might be a susceptible gene for SLE in Chinese Han subjects.</p>
<p>As mentioned previously, SLE is a highly heterogeneous autoimmune disease. The data concerning the influence of CXCL12-3′G801A polymorphism on the clinical manifestations of SLE yielded conflicting results. Ye et al.<sup><xref ref-type="bibr" rid="bibr17-0961203311435266">17</xref></sup> did not find any association of CXCL12-3′G801A polymorphism with clinical features in 143 SLE patients, whereas Lima et al.<sup><xref ref-type="bibr" rid="bibr19-0961203311435266">19</xref></sup> demonstrated that CXCL12-3′G801A homozygous A/A genotype is associated with the incidence of antiphospholipid syndrome (APS) in lupus patients, and Warchoł et al.<sup><xref ref-type="bibr" rid="bibr18-0961203311435266">18</xref></sup> observed that the CXCL12-3′801 A/A and G/A genotypes contributed to renal manifestations of SLE. We did not observe a contribution of CXCL12-3′G801A genotypes to APS (results not shown) and A/A and G/A genotypes with renal manifestations of SLE. However, we observed a significant association of CXCL12-3′G801A G/G genotype with dermal and renal manifestations of SLE.</p>
<p>The presence of autoantibodies in serum is a hallmark of SLE, and it is widely understood that inflammation and deposition of antibodies and complement exist in affected organs in SLE patients.<sup><xref ref-type="bibr" rid="bibr20-0961203311435266">20</xref>,<xref ref-type="bibr" rid="bibr21-0961203311435266">21</xref></sup> And a large amount of retrospective studies have documented that auto-antibodies associate to specific clinical manifestations of SLE.<sup><xref ref-type="bibr" rid="bibr22-0961203311435266">22</xref></sup><sup>–24</sup> Accordingly, we compared the positive rates of auto-antibodies among SLE patients with different CXCL12-3′G801A genotypes and the results showed that the incidence of anti-dsDNA and anti-nucleosome antibody is significantly higher in those patients with G/G homozygote than that in patients with G/A or A/A genotypes. Anti-dsDNA antibody and anti-nucleosome antibody are thought to be involved in lupus nephritis and skin disease.<sup><xref ref-type="bibr" rid="bibr22-0961203311435266">22</xref>,<xref ref-type="bibr" rid="bibr25-0961203311435266">25</xref>,<xref ref-type="bibr" rid="bibr26-0961203311435266">26</xref></sup> Thus, the increased involvement of kidney in those patients with homozygous G/G genotype could be indirectly explained by the association of homozygous G/G genotype with anti-dsDNA antibody and anti-nucleosome antibody. The data concerning the association of CXCL12-3′G801A polymorphism with the occurrence of auto-antibodies was not available in the studies conducted by Ye et al. and Lima G et al.<sup><xref ref-type="bibr" rid="bibr17-0961203311435266">17</xref>,<xref ref-type="bibr" rid="bibr19-0961203311435266">19</xref></sup> While, no association of CXCL12‐3′G801A polymorphism with the production of auto-antibodies was reported by Warchoł et al. in 150 Polish SLE patients.<sup><xref ref-type="bibr" rid="bibr18-0961203311435266">18</xref></sup></p>
<p>The discrepancies in the influence of CXCL12-3′G801A polymorphism on the clinical manifestations and auto-antibody production of SLE between others’ and our findings could be due to differences in the racial structure of these investigated groups, which ethnicity-specific factors might be contributing to the conflicting results.<sup><xref ref-type="bibr" rid="bibr13-0961203311435266">13</xref>,<xref ref-type="bibr" rid="bibr27-0961203311435266">27</xref></sup> Also, sample size may be an important influencing factor which should not be neglected, and relatively small sample limits the authentic association of gene variant with disease. Moreover, exposure to varying environmental factors in patients with distinct CXCL12-3′G801A genotypes can also have a disparate effect on SLE manifestation.</p>
<p>CXCL12 protein is a critical molecule in the pathogenesis of SLE. Robak<sup><xref ref-type="bibr" rid="bibr6-0961203311435266">6</xref></sup> reported that serum concentration of CXCL12α was elevated significantly in SLE patients compared with that in control individuals. Wang et al.<sup><xref ref-type="bibr" rid="bibr28-0961203311435266">28</xref>,<xref ref-type="bibr" rid="bibr29-0961203311435266">29</xref></sup> found that CXCL12α and its receptor CXCR4 were significantly up-regulated in nephritic kidney in murine models of lupus and SLE patients. To elucidate the mechanism by which CXCL12-3′G801A G/G homozygote could influence the risk of susceptibility and clinical manifestations, we further tested plasma CXCL12α expression in SLE patients. We also demonstrated that the plasma level of CXCL12α is significantly increased in SLE patients compared with that in healthy controls. Moreover, the plasma levels of CXCL12α were only significantly higher in SLE patients with G/G homozygote than those in healthy controls carrying the same genotype (<italic>p</italic> = 0.002). No difference in the plasma levels of CXCL12α was found between SLE patients and healthy controls carrying G/A or A/A genotype. This result implied that the increased production of CXCL12α in SLE was mainly due to the production of this molecule by the patients carrying the G/G homozygote, and that the G/G homozygote-associated expression of CXCL12α might contribute to the development of nephritis in patients with G/G homozygote.</p>
<p>Although the CXCL12-3′G801A polymorphism is located in the 3′UTR of the SDF1β but not the SDF-1α transcript, and does not have a direct functional effect on CXCL12/SDF-1α expression in vitro,<sup><xref ref-type="bibr" rid="bibr30-0961203311435266">30</xref></sup> there are some evidences indicating that the CXCL12-3′G801A polymorphism might be a functionally neutral marker which is in linkage disequilibrium with a functional polymorphism located elsewhere at the CXCL12α locus.<sup><xref ref-type="bibr" rid="bibr30-0961203311435266">30</xref></sup><sup>–32</sup> Thus, the CXCL12-3′G801A polymorphism can possibly have an influence on CXCL12/SDF-1α levels.<sup><xref ref-type="bibr" rid="bibr27-0961203311435266">27</xref></sup> Also, different populations may have different genetic structure and linkage disequilibrium patterns, which may explain the different association of CXCL12 SNPs with CXCL12/SDF-1 levels in different ethnic groups.</p>
<p>In conclusion, CXCL12-3′G801A polymorphism is involved in the susceptibility of SLE in a Chinese Han population. The G/G homozygote might influence the development of lupus nephritis through increasing the products of pathological antibodies and CXCL12 protein. Nevertheless further studies should be conducted to define the authentic role of CXCL12 in SLE.</p></sec>
</body>
<back>
<sec id="sec12-0961203311435266"><title>Funding</title>
<p>This work was supported by the Chinese Ministry of Health (grant number 2008BA159B02), the Health Department of Sichuan Province (grant number 080113) and North Sichuan Medical College (grant number KFJJ(08)-05).</p></sec>
<sec id="sec13-0961203311435266"><title>Conflict of interest statement</title>
<p>None declared.</p></sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203311435266"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lettre</surname><given-names>G</given-names></name><name><surname>Rioux</surname><given-names>JD</given-names></name></person-group>. <article-title>Autoimmune diseases: Insights from genome‐wide association studies</article-title>. <source>Hum Mol Genet</source> <year>2008</year>; <volume>15</volume>: <fpage>R116</fpage>–<lpage>R121</lpage>.</citation></ref>
<ref id="bibr2-0961203311435266"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>FX</given-names></name><name><surname>Wu</surname><given-names>LJ</given-names></name><name><surname>Luo</surname><given-names>XY</given-names></name><etal/></person-group>. <article-title>Lack of association between HLA‐G 14‐bp polymorphism and systemic lupus erythematosus in a Han Chinese population</article-title>. <source>Lupus</source> <year>2009</year>; <volume>18</volume>: <fpage>1259</fpage>–<lpage>1266</lpage>.</citation></ref>
<ref id="bibr3-0961203311435266"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harley</surname><given-names>JB</given-names></name><name><surname>Kelly</surname><given-names>JA</given-names></name><name><surname>Kaufman</surname><given-names>KM</given-names></name></person-group>. <article-title>Unraveling the genetics of systemic lupus erythematosus</article-title>. <source>Springer Semin Immunopathol</source> <year>2006</year>; <volume>28</volume>: <fpage>119</fpage>–<lpage>130</lpage>.</citation></ref>
<ref id="bibr4-0961203311435266"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rovin</surname><given-names>BH</given-names></name></person-group>. <article-title>The chemokine network in systemic lupus erythematous nephritis</article-title>. <source>Front Biosci</source> <year>2008</year>; <volume>13</volume>: <fpage>904</fpage>–<lpage>922</lpage>.</citation></ref>
<ref id="bibr5-0961203311435266"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname><given-names>BF</given-names></name><name><surname>Mohan</surname><given-names>C</given-names></name></person-group>. <article-title>Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus</article-title>. <source>Expert Opin Ther Targets</source> <year>2009</year>; <volume>13</volume>: <fpage>1147</fpage>–<lpage>1153</lpage>.</citation></ref>
<ref id="bibr6-0961203311435266"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robak</surname><given-names>E</given-names></name><name><surname>Kulczycka</surname><given-names>L</given-names></name><name><surname>Sysa‐Jedrzejowska</surname><given-names>A</given-names></name><name><surname>Wierzbowska</surname><given-names>A</given-names></name><name><surname>Robak</surname><given-names>T</given-names></name></person-group>. <article-title>Circulating proangiogenic molecules PIGF, SDF‐1 and sVCAM‐1 in patients with systemic lupus erythematosus</article-title>. <source>Eur Cytokine Netw</source> <year>2007</year>; <volume>18</volume>: <fpage>181</fpage>–<lpage>187</lpage>.</citation></ref>
<ref id="bibr7-0961203311435266"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balabanian</surname><given-names>K</given-names></name><name><surname>Couderc</surname><given-names>J</given-names></name><name><surname>Bouchet‐Delbos</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Role of the chemokine stromal cell‐derived factor 1 in autoantibody production and nephritis in murine lupus</article-title>. <source>J Immunol</source> <year>2003</year>; <volume>170</volume>: <fpage>3392</fpage>–<lpage>3400</lpage>.</citation></ref>
<ref id="bibr8-0961203311435266"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Cecil</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>SB</given-names></name><etal/></person-group>. <article-title>Identification and expression of novel isoforms of human stromal cell‐derived factor 1</article-title>. <source>Gene</source> <year>2006</year>; <volume>374</volume>: <fpage>174</fpage>–<lpage>179</lpage>.</citation></ref>
<ref id="bibr9-0961203311435266"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Winkler</surname><given-names>C</given-names></name><name><surname>Modi</surname><given-names>W</given-names></name><name><surname>Smith</surname><given-names>MW</given-names></name><etal/></person-group>. <article-title>Genetic restriction of AIDS pathogenesis by an SDF‐1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC)</article-title>. <source>Science</source> <year>1998</year>; <volume>279</volume>: <fpage>389</fpage>–<lpage>393</lpage>.</citation></ref>
<ref id="bibr10-0961203311435266"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dommange</surname><given-names>F</given-names></name><name><surname>Cartron</surname><given-names>G</given-names></name><name><surname>Espanel</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>GOELAMS Study Group. CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia</article-title>. <source>FASEB J</source> <year>2006</year>; <volume>20</volume>: <fpage>1913</fpage>–<lpage>1915</lpage>.</citation></ref>
<ref id="bibr11-0961203311435266"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pemberton</surname><given-names>NC</given-names></name><name><surname>Paneesha</surname><given-names>S</given-names></name><name><surname>Hiller</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>The SDF‐1 G &gt; A polymorphism at position 801 plays no role in multiple myeloma but may contribute to an inferior cause‐specific survival in chronic lymphocytic leukemia</article-title>. <source>Leuk Lymphoma</source> <year>2006</year>; <volume>47</volume>: <fpage>1239</fpage>–<lpage>1244</lpage>.</citation></ref>
<ref id="bibr12-0961203311435266"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>SC</given-names></name><name><surname>Lin</surname><given-names>PC</given-names></name><name><surname>Yang</surname><given-names>SH</given-names></name><name><surname>Wang</surname><given-names>HS</given-names></name><name><surname>Li</surname><given-names>AF</given-names></name><name><surname>Lin</surname><given-names>JK</given-names></name></person-group>. <article-title>SDF‐1alpha G801A polymorphism predicts lymph node metastasis in stage T3 colorectal cancer</article-title>. <source>Ann Surg Oncol</source> <year>2009</year>; <volume>16</volume>: <fpage>2323</fpage>–<lpage>2330</lpage>.</citation></ref>
<ref id="bibr13-0961203311435266"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Colobran</surname><given-names>R</given-names></name><name><surname>Pujol‐Borrell</surname><given-names>R</given-names></name><name><surname>Armengol</surname><given-names>MP</given-names></name><name><surname>Juan</surname><given-names>M</given-names></name></person-group>. <article-title>The chemokine network. II. On how polymorphisms and alternative splicing increase the number of molecular species and configure intricate patterns of disease susceptibility</article-title>. <source>Clin Exp Immunol</source> <year>2007</year>; <volume>150</volume>: <fpage>1</fpage>–<lpage>12</lpage>.</citation></ref>
<ref id="bibr14-0961203311435266"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name></person-group>. <article-title>Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1997</year>; <volume>40</volume>: <fpage>1725</fpage>–<lpage>1725</lpage>.</citation></ref>
<ref id="bibr15-0961203311435266"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ide</surname><given-names>A</given-names></name><name><surname>Kawasaki</surname><given-names>E</given-names></name><name><surname>Abiru</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Stromal‐cell derived factor‐1 chemokine gene variant is associated with type 1 diabetes age at onset in Japanese population</article-title>. <source>Hum Immunol</source> <year>2003</year>; <volume>64</volume>: <fpage>973</fpage>–<lpage>8</lpage>.</citation></ref>
<ref id="bibr16-0961203311435266"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manetti</surname><given-names>M</given-names></name><name><surname>Liakouli</surname><given-names>V</given-names></name><name><surname>Fatini</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Association between a stromal cell‐derived factor 1 (SDF‐1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis</article-title>. <source>Ann Rheum Dis</source> <year>2009</year>; <volume>68</volume>: <fpage>408</fpage>–<lpage>411</lpage>.</citation></ref>
<ref id="bibr17-0961203311435266"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>DQ</given-names></name><name><surname>Hu</surname><given-names>YS</given-names></name><name><surname>Li</surname><given-names>XP</given-names></name><etal/></person-group>. <article-title>The correlation between monocyte chemoattractant protein‐1 and the arthritis of systemic lupus erythematosus among Chinese</article-title>. <source>Arch Dermatol Res</source> <year>2005</year>; <volume>296</volume>: <fpage>366</fpage>–<lpage>371</lpage>.</citation></ref>
<ref id="bibr18-0961203311435266"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warchoł</surname><given-names>T</given-names></name><name><surname>Lianeri</surname><given-names>M</given-names></name><name><surname>Lącki</surname><given-names>JK</given-names></name><name><surname>Jagodziński</surname><given-names>PP</given-names></name></person-group>. <article-title>SDF1‐3' G801A polymorphisms in Polish patients with systemic lupus erythematosus</article-title>. <source>Mol Biol Rep</source> <year>2010</year>; <volume>37</volume>: <fpage>3121</fpage>–<lpage>3125</lpage>.</citation></ref>
<ref id="bibr19-0961203311435266"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>G</given-names></name><name><surname>Soto-Vega</surname><given-names>E</given-names></name><name><surname>Atisha‐Fregoso</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>MCP‐1, RANTES, and SDF‐1 polymorphisms in Mexican patients with systemic lupus erythematosus</article-title>. <source>Hum Immunol</source> <year>2007</year>; <volume>68</volume>: <fpage>980</fpage>–<lpage>985</lpage>.</citation></ref>
<ref id="bibr20-0961203311435266"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>XW</given-names></name><name><surname>Sun</surname><given-names>CY</given-names></name><name><surname>Dai</surname><given-names>M</given-names></name><name><surname>Yan</surname><given-names>YC</given-names></name><name><surname>Yang</surname><given-names>CD</given-names></name></person-group>. <article-title>Association between anti‐beta2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: a prospective study of 155 cases</article-title>. <source>Lupus</source> <year>2010</year>; <volume>19</volume>: <fpage>1195</fpage>–<lpage>1203</lpage>.</citation></ref>
<ref id="bibr21-0961203311435266"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Ao</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: A prospective study of 124 cases</article-title>. <source>Arthritis Res Ther</source> <year>2009</year>; <volume>11</volume>: <fpage>R93</fpage>–<lpage>R93</lpage>.</citation></ref>
<ref id="bibr22-0961203311435266"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>A</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name></person-group>. <article-title>Systemic lupus erythematosus</article-title>. <source>N Engl J Med</source> <year>2008</year>; <volume>358</volume>: <fpage>929</fpage>–<lpage>939</lpage>.</citation></ref>
<ref id="bibr23-0961203311435266"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jurencák</surname><given-names>R</given-names></name><name><surname>Fritzler</surname><given-names>M</given-names></name><name><surname>Tyrrell</surname><given-names>P</given-names></name><name><surname>Hiraki</surname><given-names>L</given-names></name><name><surname>Benseler</surname><given-names>S</given-names></name><name><surname>Silverman</surname><given-names>E</given-names></name></person-group>. <article-title>Autoantibodies in pediatric systemic lupus erythematosus: ethnic grouping, cluster analysis, and clinical correlations</article-title>. <source>J Rheumatol</source> <year>2009</year>; <volume>36</volume>: <fpage>416</fpage>–<lpage>421</lpage>.</citation></ref>
<ref id="bibr24-0961203311435266"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ao</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>XW</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>CD</given-names></name></person-group>. <article-title>Anti‐annexin II antibody is associated with thrombosis and/or pregnancy morbidity in antiphospholipid syndrome and systemic lupus erythematosus with thrombosis</article-title>. <source>Rheumatol Int</source> <year>2011</year>; <volume>31</volume>: <fpage>865</fpage>–<lpage>869</lpage>.</citation></ref>
<ref id="bibr25-0961203311435266"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manson</surname><given-names>JJ</given-names></name><name><surname>Ma</surname><given-names>A</given-names></name><name><surname>Rogers</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Relationship between anti‐dsDNA, anti‐nucleosome and anti‐alpha‐actinin antibodies and markers of renal disease in patients with lupus nephritis: A prospective longitudinal study</article-title>. <source>Arthritis Res Ther</source> <year>2009</year>; <volume>11</volume>: <fpage>R154</fpage>–<lpage>R154</lpage>.</citation></ref>
<ref id="bibr26-0961203311435266"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Souza</surname><given-names>A</given-names></name><name><surname>da Silva</surname><given-names>LM</given-names></name><name><surname>Oliveira</surname><given-names>FR</given-names></name><name><surname>Roselino</surname><given-names>AM</given-names></name><name><surname>Louzada‐Junior</surname><given-names>P</given-names></name></person-group>. <article-title>Anti‐nucleosome and anti‐chromatin antibodies are present in active systemic lupus erythematosus but not in the cutaneous form of the disease</article-title>. <source>Lupus</source> <year>2009</year>; <volume>18</volume>: <fpage>223</fpage>–<lpage>229</lpage>.</citation></ref>
<ref id="bibr27-0961203311435266"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>R</given-names></name><name><surname>Nishioka</surname><given-names>T</given-names></name><name><surname>Soemantri</surname><given-names>A</given-names></name><name><surname>Ishida</surname><given-names>T</given-names></name></person-group>. <article-title>Allele‐specific transcript quantification detects haplotypic variation in the levels of the SDF‐1 transcripts</article-title>. <source>Hum Mol Genet</source> <year>2005</year>; <volume>14</volume>: <fpage>1579</fpage>–<lpage>1585</lpage>.</citation></ref>
<ref id="bibr28-0961203311435266"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Fairhurst</surname><given-names>AM</given-names></name><name><surname>Tus</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>CXCR4/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus</article-title>. <source>J Immunol</source> <year>2009</year>; <volume>82</volume>: <fpage>4448</fpage>–<lpage>4458</lpage>.</citation></ref>
<ref id="bibr29-0961203311435266"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Guilpain</surname><given-names>P</given-names></name><name><surname>Chong</surname><given-names>BF</given-names></name><etal/></person-group>. <article-title>Dysregulated expression of CXCR4/CXCL12 in subsets of patients with systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>2010</year>; <volume>62</volume>: <fpage>3436</fpage>–<lpage>3446</lpage>.</citation></ref>
<ref id="bibr30-0961203311435266"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arya</surname><given-names>SK</given-names></name><name><surname>Ginsberg</surname><given-names>CC</given-names></name><name><surname>Davis‐Warren</surname><given-names>A</given-names></name><name><surname>D'Costa</surname><given-names>J</given-names></name></person-group>. <article-title>In vitro phenotype of SDF1 gene mutant that delays the onset of human immunodeficiency virus disease in vivo</article-title>. <source>J Hum Virol</source> <year>1999</year>; <volume>2</volume>: <fpage>133</fpage>–<lpage>138</lpage>.</citation></ref>
<ref id="bibr31-0961203311435266"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagasawa</surname><given-names>T</given-names></name><name><surname>Kikutani</surname><given-names>H</given-names></name><name><surname>Kishimoto</surname><given-names>T</given-names></name></person-group>. <article-title>Molecular cloning and structure of a pre‐B‐cell growth‐stimulating factor</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>1994</year>; <volume>91</volume>: <fpage>2305</fpage>–<lpage>2309</lpage>.</citation></ref>
<ref id="bibr32-0961203311435266"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shirozu</surname><given-names>M</given-names></name><name><surname>Nakano</surname><given-names>T</given-names></name><name><surname>Inazawa</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Structure and chromosomal localization of the human stromal cell‐derived factor 1 (SDF1) gene</article-title>. <source>Genomics</source> <year>1995</year>; <volume>28</volume>: <fpage>495</fpage>–<lpage>500</lpage>.</citation></ref>
</ref-list>
</back>
</article>